⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18231931 | 0.70 | — | — | |
| SCHEMBL28628510 | 0.67 | — | — | |
| SCHEMBL1425908 | 0.67 | — | — | |
| SCHEMBL51387 | 0.67 | — | — | |
| SCHEMBL16312835 | 0.67 | — | — | |
| SCHEMBL243254 | 0.67 | — | — | |
| SCHEMBL331337 | 0.67 | — | — | |
| SCHEMBL175942 | 0.64 | — | — | |
| SCHEMBL868391 | 0.64 | — | — | |
| SCHEMBL23721 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185009-A1 | Coated catheters | IMARX THERAPEUTICS, INC. (US) | 2007-08-09 | — | — | US | claimed |
| WO-2007084642-A2 | COATED CATHETERS | IMARX THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | claimed |
| EP-1689365-A1 | DRUG DELIVERY VEHICLES AND USES THEREOF | Pharmexa A/S (DK) | 2006-08-16 | — | — | EP | claimed |
| WO-2005053642-A1 | DRUG DELIVERY VEHICLES AND USES THEREOF | PHARMEXA A/S (DK) | 2005-06-16 | — | — | WO | claimed |
| EP-1537858-A1 | Drug delivery vehicles and uses thereof | Vectron Therapeutics AG (DE) | 2005-06-08 | — | — | EP | claimed |
| EP-0841896-B1 | REVERSE GELS COMPRISING A CONTINUOUS FLUORINATED PHASE | ALLIANCE PHARMA (US) | 2002-11-13 | — | — | EP | claimed |
| US-5980936-A | Multiple emulsions comprising a hydrophobic continuous phase | ALLIANCE PHARMACEUTICAL CORP. (US) | 1999-11-09 | — | — | US | claimed |
| EP-0841896-A1 | REVERSE GELS COMPRISING A CONTINUOUS FLUORINATED PHASE | ALLIANCE PHARMACEUTICAL CORPORATION (US) | 1998-05-20 | — | — | EP | claimed |
| EP-0833608-A2 | REVERSE FLUOROCARBON EMULSION COMPOSITIONS FOR DRUG DELIVERY | ALLIANCE PHARMACEUTICAL CORPORATION (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1998005301-A1 | MULTIPLE EMULSIONS COMPRISING A HYDROPHOBIC CONTINUOUS PHASE | ALLIANCE PHARMACEUTICAL CORP. (US) | 1998-02-12 | — | — | WO | claimed |
| WO-1997003644-A1 | REVERSE GELS COMPRISING A CONTINUOUS FLUORINATED PHASE | ALLIANCE PHARMACEUTICAL CORP. (US) | 1997-02-06 | — | — | WO | claimed |
| WO-1996040057-A2 | REVERSE FLUOROCARBON EMULSION COMPOSITIONS FOR DRUG DELIVERY | ALLIANCE PHARMACEUTICAL CORP. (US) | 1996-12-19 | — | — | WO | claimed |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | JINA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2022265864-A9 | TIM-3 MODULATES ANTI-TUMOR IMMUNITY BY REGULATING INFLAMMASOME ACTIVATION | THE BRIGHAM AND WOMEN’S HOSPITAL, INC (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022265864-A2 | TIM-3 MODULATES ANTI-TUMOR IMMUNITY BY REGULATING INFLAMMASOME ACTIVATION | THE BRIGHAM AND WOMEN’S HOSPITAL, INC (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20210177752-A1 | ENDOXIFEN METHODS AND COMPOSITIONS FOR INHIBITION OF PROTEIN KINASE C | JINA PHARMACEUTICALS, INC. | 2021-06-17 | — | — | US | disclosed |
| EP-0841896-A1 | REVERSE GELS COMPRISING A CONTINUOUS FLUORINATED PHASE | ALLIANCE PHARMACEUTICAL CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| EP-0833608-A2 | REVERSE FLUOROCARBON EMULSION COMPOSITIONS FOR DRUG DELIVERY | ALLIANCE PHARMACEUTICAL CORPORATION (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997003644-A1 | REVERSE GELS COMPRISING A CONTINUOUS FLUORINATED PHASE | ALLIANCE PHARMACEUTICAL CORP. (US) | 1997-02-06 | — | — | WO | disclosed |
| WO-1996040057-A2 | REVERSE FLUOROCARBON EMULSION COMPOSITIONS FOR DRUG DELIVERY | ALLIANCE PHARMACEUTICAL CORP. (US) | 1996-12-19 | — | — | WO | disclosed |